Auxogyn Inc., a Menlo Park, Calif.-based company that focuses on products for women’s reproductive health, has closed a final tranche in its Series A financing.
Investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures.
The company, which has now raised $20m in total funding, has already developed its first product, Early Embryo Viability Assessment (Eeva), which provides quantitative information regarding embryo development to assist reproductive specialists in optimizing the treatment path for their patients undergoing In vitro fertilization (IVF) procedures.
Led by president and CEO Lissa Goldenstein, Auxogyn intends to commercialize Eeva in the second half of the year.
FinSMEs
02/02/2012